Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
FRA:UNJ's Current Ratio is ranked worse than 54.7% of 1000
companies
in the Drug Manufacturers industry
Industry Median: 2
vs FRA:UNJ: 1.83
United Laboratories International Holdings (FRA:UNJ) Current Ratio Explanation
The current ratio can give a sense of the efficiency of a company's operating cycle or its ability to turn its product into cash. Companies that have trouble getting paid on their receivables or have long inventory turnover can run into liquidity problems because they are unable to alleviate their obligations. Because business operations differ in each industry, it is always more useful to compare companies within the same industry.
Acceptable current ratios vary from industry to industry and are generally between 1 and 3 for healthy businesses.
The higher the current ratio, the more capable the company is of paying its obligations. A ratio under 1 suggests that the company would be unable to pay off its obligations if they came due at that point. While this shows the company is not in good financial health, it does not necessarily mean that it will go bankrupt - as there are many ways to access financing - but it is definitely not a good sign.
If all other things were equal, a creditor, who is expecting to be paid in the next 12 months, would consider a high current ratio to be better than a low current ratio, because a high current ratio means that the company is more likely to meet its liabilities which fall due in the next 12 months.
United Laboratories International Holdings Current Ratio Related Terms
United Laboratories International Holdings Current Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
United Laboratories International Holdings Current Ratio Chart
United Laboratories International Holdings Annual Data
For the Drug Manufacturers - Specialty & Generic subindustry, United Laboratories International Holdings's Current Ratio, along with its competitors' market caps and Current Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
United Laboratories International Holdings Current Ratio vs Drug Manufacturers Industry
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
United Laboratories International Holdings (FRA:UNJ) has a Current Ratio of 1.83 as of Dec. 2025. This is 14% above median its historical median of 1.61. Over the past decade, United Laboratories International Holdings' Current Ratio has ranged from 0.86 to 2.08. According to the industry distribution chart, United Laboratories International Holdings ranks #547 out of 1000 companies in the Drug Manufacturers industry, placing it in the top 54.7%.
Is United Laboratories International Holdings' Current Ratio too high?
United Laboratories International Holdings' current Current Ratio of 1.83 is 14% above median its 10-year median of 1.61. Over the past 10 years, this metric has ranged from a low of 0.86 to a high of 2.08. The Drug Manufacturers industry median Current Ratio is 2.00. United Laboratories International Holdings' value of 1.83 is 8.5% below this industry median. Based on the distribution chart, United Laboratories International Holdings ranks #547 out of 1000 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, United Laboratories International Holdings has a GF Score™ of 90/100, reflecting its overall financial health beyond just this single metric.
How does United Laboratories International Holdings' Current Ratio compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, United Laboratories International Holdings ranks #547 out of 1000 companies for Current Ratio. This places United Laboratories International Holdings in the lower half of its industry. The industry median Current Ratio is 2.00. United Laboratories International Holdings' value of 1.83 is 8.5% below this benchmark. Historically, United Laboratories International Holdings' own Current Ratio has ranged from 0.86 to 2.08 over the past decade. While the company's 10-year median is 1.61 vs. the industry median of 2.00, United Laboratories International Holdings has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Ratio for a Drug Manufacturers company?
The median Current Ratio among Drug Manufacturers companies is 2.00, based on 1,000 companies in the industry. Companies in the top quartile (top 25%) have a Current Ratio significantly above this median, while those in the bottom quartile fall well below. However, Current Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. United Laboratories International Holdings's current Current Ratio of 1.83 is 8.5% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Ratio mean?
A high Current Ratio can signal that a stock is expensive relative to its fundamentals. For the Drug Manufacturers industry, the median Current Ratio is 2.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. United Laboratories International Holdings's current Current Ratio is 1.83, which is 14% above median its own 10-year median of 1.61. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is United Laboratories International Holdings stock overvalued right now?
United Laboratories International Holdings (FRA:UNJ) has a current Current Ratio of 1.83. The stock's GF Value™ is €0.96, compared to a current price of €1.00 — trading 4.2% above its estimated fair value. The current Current Ratio is 1.83, which is 14% above median its 10-year median of 1.61 and 8.5% below the Drug Manufacturers industry median of 2.00. United Laboratories International Holdings' overall GF Score™ is 90/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Ratio calculated?
Current Ratio is calculated from a company's financial statements. For United Laboratories International Holdings (FRA:UNJ), the current Current Ratio is 1.83 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is United Laboratories International Holdings (FRA:UNJ) Overvalued in 2026?
Based on GuruFocus' analysis, United Laboratories International Holdings stock appears to be overvalued.
The current stock price of €1.00 is trading 4.2% above its estimated GF Value™ of €0.96.
Key valuation signals for FRA:UNJ:
Current Ratio: 1.83 (14% above median its 10-year median of 1.61)
GF Value™: €0.96 vs. price of €1.00 (4.2% above fair value)
Industry Position: 8.5% below the Drug Manufacturers median (#547 of 1000)
No single metric tells the full story. See the FRA:UNJ stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
United Laboratories International Holdings Business Description
United Laboratories International Holdings Ltd is mainly engaged in the research and development, production and sales of pharmaceuticals. The company operates in three segments: Intermediate products, Bulk medicine, and Finished products. The company's Finished products segment includes antibiotic products, insulin series products, and other medicines. The vast majority of the company's revenue is derived from its Finished products segment, followed by Bulk medicine. The majority of the company's sales are generated in China, followed by Europe, India and other countries.
90GF Score
Get the complete analysis for FRA:UNJ
Current Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:UNJ has been successfully added to your 
